Two kinds of rhenium labeled radiopharmaceuticals for therapy of the human brain glioma were prepared. Anti-human brain glioma monoclonal antibody (McAb-SZ39) was directly labeled with ~(186)ReO_4~-. When ascorbic acid was used as reduction agent of antibody and the reduction of ~(186)ReO_4~- was finished in sodium gluconate solution (pH=2.54), the labeling efficiency was 96.2%. After purification, the labeled products were tested in respect of immunoreactivity, in vitro stability as well as inhibitory efficiency against human glioma transplanted in nude mice. ~(188)ReO_4~- labeled colloid was synthesized by using a two-step method. The size of radiocolloid particles was around 2～5μn, and the radiochemical yield was over 95%. Nude mice Experiments demonstrated that the inhibitory efficiency against human brain glioma of ~(188)Re-colloid and ~(188)Re-McAb-SZ39 was 90% and 65%, respectively. Two kinds of rhenium labeled radiopharmaceuticals for therapy of the human brain glioma were prepared. Anti-human brain glioma monoclonal antibody (McAb-SZ39) was directly labeled with ~ (186) ReO_4 ~ -. When ascorbic acid was used as a reduction agent of antibody After purification, the labeling products were tested in respect of immunoreactivity, in vitro stability as well as inhibitory (186) ReO_4 ~ - finished in sodium gluconate solution (pH = 2.54) efficiency against human glioma transplanted in nude mice. ~ (188) ReO_4 ~ - labeled colloid was synthesized by using a two-step method. The size of the radiocolloid particles was around 2 ~ 5μn, and the radiochemical yield was over 95%. Nude mice Experiments demonstrated that the inhibitory efficiency against human brain glioma of ~ (188) Re-colloid and ~ (188) Re-McAb-SZ39 was 90% and 65%, respectively.